Navigation Links
Drug Failed to Reduce Heart Attack Risk After Bypass
Date:4/1/2008

MC-1 had no benefit for postoperative stroke, atrial fibrillation or kidney function

TUESDAY, April 1 (HealthDay News) -- Researchers found that giving patients MC-1, a naturally occurring metabolite of vitamin B6, before and after bypass surgery didn't reduce the risk of heart attack or cardiovascular death.

"Coronary artery bypass graft (CABG) surgery is one of the most important therapeutic options for relieving angina and improving survival and quality of life in patients with multi-vessel coronary artery disease," the Duke University scientists wrote. "It is the most commonly performed cardiac surgical procedure in the world, and, in 2005, more than 250,000 CABG procedures were performed in the United States."

But CABG surgery can lead to serious complications such as heart attack, recurrent angina, kidney problems, stroke and death. Previous research suggested that MC-1 may lower the risk of heart attack or death in high-risk patients.

A new phase 3 multi-center, randomized trial of MC-1 included 3,023 intermediate- to high-risk patients undergoing CABG surgery with cardiopulmonary bypass. It found that cardiovascular death or nonfatal heart attack 30 days after surgery occurred in 140 of 1,510 patients (9.3 percent) who received MC-1 and in 133 of 1,486 patients (9.0 percent) who received a placebo.

All-cause death was 1 percent in the MC-1 group and 0.3 percent in the placebo group at four days, and 1.9 percent in the MC-1 group and 1.5 percent in the placebo group at 30 days.

Both groups had similar levels of postoperative stroke, atrial fibrillation, kidney function, and intensive care unit and hospital lengths of stay.

The findings show that "among intermediate- to high-risk patients undergoing CABG surgery, MC-1, 250 mg/d, given immediately before and for 30 days following surgery did not reduce cardiovascular death or nonfatal (heart attack)," the study authors wrote. "Myocardial injury remains a significant problem following CABG surgery. Effective therapies to reduce perioperative morbidity and mortality are needed but remain elusive."

The study was expected to be presented April 1 at the American College of Cardiology annual meeting and was published online in the Journal of the American Medical Association. It was also expected to be published in the April 16 print issue of the journal.

More information

The U.S. National Heart, Lung, and Blood Institute has more about CABG.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, April 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. UFE Highly Effective in Cases Where Focused Ultrasound to Treat Uterine Fibroids Failed
2. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
3. Fallout From Failed AIDS Vaccine Could Dampen Research
4. Safe, Green Insecticides Can Reduce Chemical Exposure in Homes and Gardens
5. Illinois Radiologists Self-Edit Reports, Reduce Turnaround Time with SpeechQ for Radiology(TM)
6. Evanston-Northwestern Study Proves Effectiveness of MRSA Screening to Reduce Hospital Infections
7. Psychological intervention reduces postembolization pain
8. Aspirin Reduces Asthma Risk Among Older Women
9. Partnerships Report Highlights How Blue Cross Blue Shield of Michigan, Physicians and Hospitals Are Working to Save Lives, Improve Care, Reduce Costs
10. Low-Fat Dairy Reduces High Blood Pressure Risk
11. Late treatment with letrozole can reduce breast cancer recurrence risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Failed to Reduce Heart Attack Risk After Bypass 
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology: